At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
QNTM Quantum Biopharma Ltd.
Market Closed 06-18 16:00:00 EDT
3.80
-0.17
-4.28%
盘后3.72
-0.08-2.17%
19:55 EDT
High4.15Low3.70Vol166.36K
Open4.15D1 Closing3.97Amplitude11.34%
Mkt Cap24.31MTradable Cap22.54MTotal Shares6.40M
T/O635.91KT/O Rate2.80%Tradable Shares5.93M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Advances Proprietary Therapy for MS Treatment
TIPRANKS  ·  06-10
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Advances Proprietary Therapy for MS Treatment
Broadcom, Quantinuum, Strategy, Tesla, and More Stocks That Explain Today's Market -- Barrons.com
Dow Jones  ·  06-06
Broadcom, Quantinuum, Strategy, Tesla, and More Stocks That Explain Today's Market -- Barrons.com
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Builds Diversified Pipeline Across Neurological and Wellness Markets
TIPRANKS  ·  06-05
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Builds Diversified Pipeline Across Neurological and Wellness Markets
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Highlights Lucid-MS and unbuzzd(TM) Growth Opportunities on BioMedWire Podcast
TIPRANKS  ·  06-03
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Highlights Lucid-MS and unbuzzd(TM) Growth Opportunities on BioMedWire Podcast
Quantum BioPharma Engages Stocks.news For Investor Relations, Marketing Services And Lead Generation Campaigns
GlobeNewswire  ·  06-02
Quantum BioPharma Engages Stocks.news For Investor Relations, Marketing Services And Lead Generation Campaigns
Quantum BioPharma Provides Corporate Update
GlobeNewswire  ·  06-02
Quantum BioPharma Provides Corporate Update
NASDAQ TRADE HALT HALT NEWS PENDING AT 07:25 PM
Reuters  ·  06-02
NASDAQ TRADE HALT HALT NEWS PENDING AT 07:25 PM
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Reports Midpoint Enrollment Milestone in MS Imaging Study
TIPRANKS  ·  05-19
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Reports Midpoint Enrollment Milestone in MS Imaging Study
Quantum BioPharma Reaches Key Midpoint Milestone in Groundbreaking Imaging Study with Massachusetts General Hospital
GlobeNewswire  ·  05-18
Quantum BioPharma Reaches Key Midpoint Milestone in Groundbreaking Imaging Study with Massachusetts General Hospital
Press Release: Quantum Reports Strengthened Liquidity, Reduced Cash Burn, and Disciplined Cost Management in First Quarter 2026
Dow Jones  ·  05-07
Press Release: Quantum Reports Strengthened Liquidity, Reduced Cash Burn, and Disciplined Cost Management in First Quarter 2026
Quantum BioPharma Provides Corporate Update
GlobeNewswire  ·  04-28
Quantum BioPharma Provides Corporate Update
Quantum BioPharma Licensee Unbuzzd Wellness Inc. Appoints Richard Buzbuzian as CEO to Lead Nationwide Commercialization of Innovative, Clinically Validated Hangover Remedy and Alcohol Metabolism Accelerant
GlobeNewswire  ·  04-22
Quantum BioPharma Licensee Unbuzzd Wellness Inc. Appoints Richard Buzbuzian as CEO to Lead Nationwide Commercialization of Innovative, Clinically Validated Hangover Remedy and Alcohol Metabolism Accelerant
Quantum BioPharma Wins Significant Court Challenge in USD $700,000,000 Claim as Defendants Joint Motion to Dismiss Lawsuit Alleging Market Manipulation by CIBC World Markets and RBC Dominion Securities is Denied
GlobeNewswire  ·  04-02
Quantum BioPharma Wins Significant Court Challenge in USD $700,000,000 Claim as Defendants Joint Motion to Dismiss Lawsuit Alleging Market Manipulation by CIBC World Markets and RBC Dominion Securities is Denied
Quantum BioPharma Submits Investigational New Drug (IND) Application to United States Food and Drug Administration (FDA) for Lucid-MS Phase Two Clinical Trial in Multiple Sclerosis
GlobeNewswire  ·  04-01
Quantum BioPharma Submits Investigational New Drug (IND) Application to United States Food and Drug Administration (FDA) for Lucid-MS Phase Two Clinical Trial in Multiple Sclerosis
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 11:50 AM
Reuters  ·  03-30
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 11:50 AM
Quantum BioPharma Signs Binding Letter Of Intent With Allucent To Conduct Phase 2 Clinical Trial In Multiple Sclerosis
GlobeNewswire  ·  03-30
Quantum BioPharma Signs Binding Letter Of Intent With Allucent To Conduct Phase 2 Clinical Trial In Multiple Sclerosis
Quantum Biopharma Provides Corporate Update
GlobeNewswire  ·  03-28
Quantum Biopharma Provides Corporate Update
Press Release: Quantum Biopharma's 2025 Audited Year End Financial Results Maintain 'No Going Concern' Status
Dow Jones  ·  03-27
Press Release: Quantum Biopharma's 2025 Audited Year End Financial Results Maintain 'No Going Concern' Status
Quantum BioPharma Q4 EPS $(0.71) Beats $(0.93) Estimate
Benzinga  ·  03-27
Quantum BioPharma Q4 EPS $(0.71) Beats $(0.93) Estimate
Quantum Biopharma Announces Appointment of Principal Investigator for Planned Phase 2 Clinical Trial of Lucid-21-302 (Lucid-MS) in Multiple Sclerosis
GlobeNewswire  ·  03-26
Quantum Biopharma Announces Appointment of Principal Investigator for Planned Phase 2 Clinical Trial of Lucid-21-302 (Lucid-MS) in Multiple Sclerosis

Introduction

Company Name.
Quantum Biopharma Ltd.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
FSD Pharma Inc., a biotechnology company, operates in the pharmaceutical research and development business. Its lead candidate is FSD-201, an ultra-micronized palmitoylethanolamide for the treatment of inflammatory diseases. The company is also involved in the research and development of Lucid-Psych, a molecular compound identified for the treatment of mental health disorders; and Lucid-MS, a molecular compound identified for the treatment of neurodegenerative disorders. FSD Pharma Inc. was incorporated in 1998 and is headquartered in Toronto, Canada.
Issue price:
--